HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $44 to $56.
July 16, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Revolution Medicines and raises the price target from $44 to $56.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100